ALUMIS INC.

Alumis Inc. reported a net loss of $(142.2) million for the second quarter of 2026, a significant decline from a net income of $59.3 million in the prior year, primarily due to an intangible asset impairment loss of $41.8 million. Total revenue decreased to $1.66 million from $2.67 million year-over-year. Despite the operational losses, the company strengthened its financial position through a public offering in January 2026, raising $324.4 million in net proceeds, and believes it has sufficient liquidity for at least 12 months.

Alumis Inc. reported a net loss of $142.2 million for Q2 2026, with revenue of $1.7 million. The company highlighted strong clinical results for envudeucitinib in plaque psoriasis, with 54% of patients achieving complete skin clearance (PASI 100) at 48 weeks in the ONWARD3 study, and remains on track for an FDA NDA submission in Q4 2026. Alumis also anticipates Phase 2b LUMUS topline data for envudeucitinib in SLE in Q3 2026 and plans to initiate a Phase 2 trial for A-005 in Parkinson's disease in 1H 2027. The company's cash position of $502.3 million is expected to fund operations into Q4 2027.

Alumis Inc. announced positive topline results from the ONWARD3 long-term extension study for envudeucitinib, an investigational oral TYK2 inhibitor for plaque psoriasis. The data showed 54% of patients achieved complete skin clearance (PASI 100) after 48 weeks, positioning it as a potential new standard among oral therapies. The treatment maintained a favorable long-term safety profile, consistent with previous findings. The company is on track to submit a New Drug Application to the FDA in the fourth quarter of 2026.

Alumis Inc. updated its corporate presentation for investors, highlighting significant progress in its TYK2 inhibitor pipeline. The presentation detailed positive Phase 3 results for envudeucitinib in moderate-to-severe plaque psoriasis, showing leading PASI 100 responses and robust improvements in skin clearance and quality of life. The company anticipates filing an NDA for envudeucitinib in psoriasis in Q4 2026 and expects topline data from its potentially pivotal Phase 2b SLE trial in Q3 2026. Additionally, Alumis plans to initiate a Phase 2 biomarker trial for A-005 in Parkinson's disease in 1H 2027, supported by a cash runway into Q4 2027.

Alumis Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Tuesday, June 30, 2026, at 9:00 a.m. Pacific Time. Stockholders of record as of May 5, 2026, are eligible to vote on proposals including the election of three Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Proxy materials were made available on or about May 18, 2026.

Alumis Inc. reported a net loss of $93.1 million for Q1 2026, alongside significant clinical advancements for its lead asset, envudeucitinib. Phase 3 data for moderate-to-severe plaque psoriasis demonstrated robust skin clearance and quality-of-life improvements, with an NDA submission planned for Q4 2026. The company also anticipates potentially pivotal Phase 2b data for envudeucitinib in systemic lupus erythematosus in Q3 2026 and has completed a strategic review of its lonigutamab program. Alumis expects its current cash to fund operations into Q4 2027.